Janux Therapeutics Faces Downgrades Amid Phase 1 Data Concerns

Janux Therapeutics shares are trading lower after Cantor Fitzgerald downgraded its price target to $150 while BofA and Stifel cut their targets to $49 and $38 respectively, citing mixed results from the company's Phase 1 data for JANX007.